What researchers published on Mielodiszplasztikus szindróma (MDS)
8389 papers, newest first.
Showing 20 of 8389
Clinical and molecular characteristics associated with megakaryocytic dysplasia in patients with myelodysplastic syndromes.Hematology (Amsterdam, Netherlands)
ÁttekintésNovel and emerging agents for myelodysplastic syndromes/neoplasms.Expert opinion on investigational drugs
Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.Acta haematologica
New diagnostic criteria can inflate myelodysplastic syndrome survival estimates.Journal of the National Cancer Institute
SRSF2 mutations contribute to bone marrow immune microenvironment alterations.Cell death & disease
An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report.The Journal of rheumatology
Fever of Unknown Origin in Myelodysplastic Syndrome: Clinical and Laboratory Features of a Chinese Cohort.Journal of clinical medicine
AI-assisted single-cell transcriptomics defines immunosuppressive ecosystem states and CD274-centered communication networks in myelodysplastic syndrome.Frontiers in cell and developmental biology
Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.Blood
Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.Blood
Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.Haematologica
Exploring neuropsychological alterations in VEXAS syndrome.Clinical and experimental medicine
EsetismertetésMyelodysplastic Syndrome With Isolated del(5q) Coexisting With Cold Agglutinin Disease Presenting as Unexplained Hyperbilirubinemia.Cureus
Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy.Current problems in cancer
MicroRNA dysregulation in mesenchymal stromal cells in myelodysplastic syndromes and its modulation by azacitidine and bortezomib.Leukemia & lymphoma
ÁttekintésSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells.Leukemia
Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes.Blood neoplasia
PreprintPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms.bioRxiv : the preprint server for biology
Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non-Erythroid Blood Counts.Hematological oncology